Glaxo Smith Kline headquarters, London

William Barton/iStock Editorial via Getty Images

GSK plc (GSK) reported third-quarter core earnings per share above analyst expectations on Wednesday, as growth in specialty medicines helped offset weakness in vaccines.

The drugmaker reaffirmed its full-year 2026 outlook, while investors continued to assess the growth potential of newer

Source link

Discover more from Occasional Digest

Subscribe now to keep reading and get access to the full archive.

Continue reading